NewAmsterdam Pharma Company N.V. (NAMS) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
Gooimeer 2-35
Naarden, NH 1411 DC
Netherlands (Kingdom of the)
Phone
31 35 206 2971
Sector
Healthcare
Industry
Biotechnology
Employees
100
First IPO Date
February 09, 2021
| Name | Title | Pay | Year Born |
| Michael Harvey Davidson FACC Facp. | CEO, President & Executive Director | 1.14M | 1956 |
| Juliette Audet | Chief Strategy & Business Officer | 653,039 | 1987 |
| Louise Kooij | Chief Accounting Officer | 695,419 | 1976 |
| Mayur Amrat Somaiya | Chief Financial Officer | 770,393 | 1974 |
| Douglas F. Kling | Chief Operating Officer | 790,051 | 1973 |
| Johannes Jacob Pieter Kastelein FESC | Founder, Chief Scientific Officer, Member of Executive Board & Director | 808,143 | 1954 |
| Marc Ditmarsch | Chief Development Officer | 0 | 1967 |
| Chris Deluzio | Executive Vice President of Sales Enterprise Operations | 0 | N/A |
| Bob Rambo | Executive Vice President of Marketing | 0 | N/A |
| Michael F. Marino | Chief Legal Officer & Corporate Secretary | 0 | 1976 |
| Maryellen McQuade | Chief People Officer | 0 | N/A |
| Matthew Philippe | Executive VP & Head of Investor Relations | 0 | N/A |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.